BioNTech raises 2025 revenue guidance after Bristol Myers deal
PositiveFinancial Markets

BioNTech has raised its revenue guidance for 2025 following a significant deal with Bristol Myers. This adjustment reflects the company's confidence in its growth trajectory and the potential impact of its collaborations. Such partnerships are crucial in the biotech industry, as they can lead to innovative treatments and increased market presence, ultimately benefiting patients and investors alike.
— Curated by the World Pulse Now AI Editorial System











